middle.news
Radiopharm gives RAD101 a clear FDA-backed route to Phase 3
8:49am on Wednesday 4th of November, 2026 AEDT
•
Biotechnology
Read Story
Radiopharm gives RAD101 a clear FDA-backed route to Phase 3
8:49am on Wednesday 4th of November, 2026 AEDT
Key Points
FDA alignment on a single pivotal Phase 3 study for RAD101
Approximately 280 patients across multiple centres
Sensitivity and specificity set as co-primary endpoints
CRO selection targeted for the fourth quarter of 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE